Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects
Status:
Completed
Trial end date:
2019-12-26
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, randomized, four-period, crossover study in healthy females of
nonchildbearing potential and male subjects - to be conducted at a single center in the
United States.
The study will consist of a screening phase, a baseline phase, four treatment periods, and a
follow-up phone call. The 4 treatment periods are divided into two pairs (Period 1 and 2 and
Period 3 and 4), potentially separated by an intermission during which subjects will be
discharged from the research unit: Periods 1 and 2 support relative bioavailability (RBA)
estimation, while Periods 3 and 4 support estimation of PPI effects.